Gate2Brain Raises €7 Million in Recent Funding Round
Gate2Brain, a biotech company pioneering the development of therapeutics that can efficiently cross biological barriers such as the blood-brain barrier, has successfully raised €7 million in its latest funding round. This significant investment aims to bolster the company's innovative peptide-based technology platform.
Strategic Partnership with Shilpa Biocare
The funding round was led by Shilpa Biocare Pvt Ltd, which is a wholly owned subsidiary of Shilpa Medicare Limited. As a result of this investment, Shilpa Biocare now holds a 30.4% ownership stake in Gate2Brain, marking the beginning of a strategic partnership between the two entities. This collaboration is expected to enhance Gate2Brain's capacity to develop treatments for aggressive brain tumors in both children and adults.
Leadership at Gate2Brain
Gate2Brain was founded in 2020 and is led by CEO and CSO, Meritxell Teixido. Dr. Teixido commented on the funding, stating, "Gate2Brain acknowledges the continued support of its institutional partners, external advisors, investors, and business angels, whose confidence and commitment have played a key role in advancing the company’s mission and technology platform."
Use of Funds
While the company has not disclosed specific plans for the newly raised capital, such funding typically supports further research and development, scaling up production capabilities, and expanding market reach. In the biotech sector, investments are often directed towards enhancing the effectiveness of drug delivery technologies, especially those targeting the brain and central nervous system.
Biotech Investment Trends
The funding for Gate2Brain comes amid a broader trend in 2026, where significant investments are being channeled into biotech companies across Europe. Key areas of focus include cancer treatments, technologies that facilitate drug delivery to the brain, RNA-based therapies, and innovations that improve the efficiency of clinical trials. This trend underscores the growing interest in and support for advancements in medical technology and therapeutic solutions.
Gate2Brain's successful funding round highlights the potential of its technology platform to make a significant impact on the treatment of challenging medical conditions. With the backing of Shilpa Biocare, the company is well-positioned to continue its work on breaking through biological barriers to deliver more effective therapeutics.